Totus Medicines has dosed its first patient in a Phase I clinical trial of TOS-358, a first-in-class covalent PI3Kα inhibitor for the treatment of numerous cancers with known PIK3CA mutations. The Totus Accel Platform is designed to be the first biosearch technology that scans, maps, and decodes new drugs thousands of times faster than traditional […]
